People
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
The United States and other wealthy nations now stand at an important place in their COVID-19 vaccine campaigns. The question largely turns to vaccinating the remainder of the population – namely, those under 12 years.
Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.
bluebird bio and National Resilience signed a strategic alliance around cell therapies. As part of the deal, Resilience is buying bluebird’s manufacturing facility in Research Triangle Park, keeping more than 100 staffers.
“For the first time in history, medicine has become information.” That’s the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.
Bryan Dechairo, newly appointed president and CEO of Sherlock Biosciences, learned early to fill gaps and seize opportunities. Read more about his views.
As disgraced Theranos founder Elizabeth Holmes awaits her day in court, a long-awaited documentary series focused on the Stanford dropout who became a billionaire before losing it all is set to air on streaming service Hulu.
Phase one launched last week after patients who had been on placebo in Biogen’s pivotal phase III VALOR study were transitioned to active therapy.
Merck’s former chief executive officer and current executive chairman, Kenneth Frazier, has stepped down from his post at the pharmaceutical company to join venture capital firm General Catalyst as its newest chairman of health assurance initiatives.
Biosimulation is integral to drug development today, with fierce competition for expert scientists to run the simulations and interpret the results. Craig Rayner, president of Certara, a biosimulation company, is turning to Africa to unlock an untapped reservoir of talent.
PRESS RELEASES